| Prior colonization or infection with NTM (especially among those with primary immune deficiency) |
| Relapse of underlying malignancy prior to HCT |
| Myeloablative conditioning regimen |
| T cell depletion |
| Delayed time to immune reconstitution |
| Low CD4 count |
| Structural lung disease |
| Allogeneic HCT greater risk compared to autologous HCT |
| Prior colonization or infection with NTM (especially among those with primary immune deficiency) |
| Relapse of underlying malignancy prior to HCT |
| Myeloablative conditioning regimen |
| T cell depletion |
| Delayed time to immune reconstitution |
| Low CD4 count |
| Structural lung disease |
| Allogeneic HCT greater risk compared to autologous HCT |
| Prior colonization or infection with NTM (especially among those with primary immune deficiency) |
| Relapse of underlying malignancy prior to HCT |
| Myeloablative conditioning regimen |
| T cell depletion |
| Delayed time to immune reconstitution |
| Low CD4 count |
| Structural lung disease |
| Allogeneic HCT greater risk compared to autologous HCT |
| Prior colonization or infection with NTM (especially among those with primary immune deficiency) |
| Relapse of underlying malignancy prior to HCT |
| Myeloablative conditioning regimen |
| T cell depletion |
| Delayed time to immune reconstitution |
| Low CD4 count |
| Structural lung disease |
| Allogeneic HCT greater risk compared to autologous HCT |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
